Advertisement
Advertisement
U.S. Markets close in 2 hrs 25 mins
Advertisement
Advertisement
Advertisement
Advertisement

MediWound Ltd. (MDWD)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.4000+0.0300 (+2.19%)
As of 01:35PM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.3700
Open1.3500
Bid1.3600 x 800
Ask1.4000 x 1100
Day's Range1.3500 - 1.4500
52 Week Range1.2100 - 4.0100
Volume47,936
Avg. Volume121,114
Market Cap38.146M
Beta (5Y Monthly)1.14
PE Ratio (TTM)N/A
EPS (TTM)-0.3380
Earnings DateNov 14, 2022 - Nov 18, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.07
  • GlobeNewswire

    MediWound Announces Concurrent Registered Direct and Private Placement Offerings Priced At-the-Market of Approximately $30 Million

    YAVNE, Israel, Sept. 22, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD) (the “Company”), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that it has entered into a definitive securities purchase agreement with several institutional and accredited investors (the “Registered Direct Securities Purchase Agreement”) for the sale and purchase of 7,575,513 shares of the Company’s ordinary shares

  • GlobeNewswire

    EMA Accepts MediWound’s Application for Extended Indication for NexoBrid to Treat Pediatric Patients with Severe Thermal Burns

    Upon approval, NexoBrid will serve as a safe and effective non-surgical treatment option in the EU for children with severe burnsYAVNE, Israel, Sept. 20, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ: MDWD) (the “Company”), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that the European Medicines Agency (EMA) has validated for review the Type II Variation submitted by MediWound in order to ex

  • GlobeNewswire

    MediWound’s NexoBrid® Highlighted in 45 Posters and Presentations at the 19th European Burns Association Congress

    YAVNE, Israel, Sept. 12, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a fully integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced its successful and meaningful presence at the recently concluded 19th European Burns Association (EBA) Congress held in Turin, Italy on September 7-10, 2022. NexoBrid was included in 45 scientific posters and presentations by leaders in the field of burn c

Advertisement
Advertisement